Skip to content
20-F

Annual Report (Foreign)

Can-Fite BioPharma Ltd. CANF

0001213900-26-034447

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 1.65M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 725.31K sh
Shares Diluted restated FY 2025 · Dec 31, 2023 426.11K sh
Shares Outstanding FY 2025 · Dec 31, 2025 2.62M sh
Capex FY 2025 · Dec 31, 2025 $2K
Capex FY 2025 · Dec 31, 2024 $5K
Capex FY 2025 · Dec 31, 2023 $2K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$8.95M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$7.64M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$8.44M
Short Term Investments FY 2025 · Dec 31, 2025 $1K
Short Term Investments FY 2025 · Dec 31, 2024 $5K
Cash And Equivalents FY 2025 · Dec 31, 2025 $5.53M
Cash And Equivalents FY 2025 · Dec 31, 2024 $4.83M
Stockholders Equity FY 2025 · Dec 31, 2025 $5.59M
Stockholders Equity FY 2025 · Dec 31, 2024 $5.44M
Stockholders Equity FY 2025 · Dec 31, 2023 $6.24M
Stockholders Equity FY 2025 · Dec 31, 2022 $4.47M
Current Liabilities FY 2025 · Dec 31, 2025 $2.73M
Current Liabilities FY 2025 · Dec 31, 2024 $2.05M
Current Assets FY 2025 · Dec 31, 2025 $9.44M
Current Assets FY 2025 · Dec 31, 2024 $8.98M
Total Assets FY 2025 · Dec 31, 2025 $9.51M
Total Assets FY 2025 · Dec 31, 2024 $9.12M
Eps Diluted FY 2025 · Dec 31, 2025 −$5.97
Eps Diluted restated FY 2025 · Dec 31, 2024 −$10.86
Eps Diluted restated FY 2025 · Dec 31, 2023 −$17.92
Eps Basic FY 2025 · Dec 31, 2025 −$5.97
Eps Basic restated FY 2025 · Dec 31, 2024 −$10.86
Eps Basic restated FY 2025 · Dec 31, 2023 −$17.92
Rd Expense FY 2025 · Dec 31, 2025 $6.69M
Rd Expense FY 2025 · Dec 31, 2024 $5.76M
Rd Expense FY 2025 · Dec 31, 2023 $5.98M
Net Income FY 2025 · Dec 31, 2025 −$9.83M
Net Income FY 2025 · Dec 31, 2024 −$7.88M
Net Income FY 2025 · Dec 31, 2023 −$7.63M
Operating Income FY 2025 · Dec 31, 2025 −$9.95M
Operating Income FY 2025 · Dec 31, 2024 −$8.13M
Operating Income FY 2025 · Dec 31, 2023 −$8.2M
Revenue FY 2025 · Dec 31, 2025 $405K
Revenue FY 2025 · Dec 31, 2024 $674K
Revenue FY 2025 · Dec 31, 2023 $743K
Stock Issued FY 2025 · Jul 3, 2024 1.67M sh